# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Jesse Owens (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML042-SYN
- Date: 2026-05-26
- Fictional facility: St. Posthumous Health Center
- Fictional author: Clarence Whitfield-Arroyo, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Diagnosis visit: staging and biopsy results, the tumor board plan, and the thoracic oncology consultation. **S**

## History of present illness

Mr. Owens returns two weeks after the screening CT. PET-CT three days after the scan showed the 2.9 cm left upper lobe nodule and a left interlobar node to be active, with nothing in the mediastinum or elsewhere, and brain MRI the next day was clear. Endobronchial ultrasound a week ago found adenocarcinoma in the interlobar node, with four other node stations negative. PD-L1 is 40 percent, and tissue sequencing, back yesterday, shows a KRAS G12C mutation and no EGFR, ALK or other targetable alteration. The thoracic tumor board reviewed him five days ago. He had pulmonary function tests this morning and saw Dr. Halvorsen-Pierce at midday. He still has his usual morning cough, no breathlessness, and has lost no weight. He is still smoking a pack a day and now wants to stop: the scan has convinced him. He has had no thoughts of self-harm. **S**

| Element | Detail |
|---|---|
| Diagnosis | Adenocarcinoma of the left upper lobe, cT1c N1 M0, stage IIB; resectable |
| Procedures since the first visit | PET-CT, brain MRI, endobronchial ultrasound with systematic node sampling, pulmonary function tests |
| Biomarkers | PD-L1 40 percent; KRAS G12C; no EGFR, ALK, ROS1, BRAF, MET exon 14, RET, NTRK or HER2 alteration |
| Tumor board | Three cycles of nivolumab with platinum chemotherapy, restaging, then lobectomy |
| His questions | Whether it can be cured; why surgery is not first; whether stopping smoking now makes any difference; whether he can keep speaking at schools |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No weight loss, fever or night sweats; weight 76.6 kg |
| Respiratory | Positive | Usual morning cough with a little clear sputum; no breathlessness or hemoptysis |
| Cardiovascular | Negative | No chest pain or leg swelling |
| Musculoskeletal | Negative | No bone pain |
| Neurological | Negative | No headache, weakness or numbness |
| Psychiatric | Positive | Worried but hopeful; PHQ-9 6, GAD-7 7; no thoughts of self-harm |

6 systems reviewed. **S**

## Current medications

- Varenicline 0.5 mg oral tablet: one tablet daily for three days, then one tablet twice daily for four days (starting week), with a quit date on day 8 **S**
- Folic acid 1 mg oral tablet, one tablet daily from one week before the first pemetrexed dose until three weeks after the last **S**

## Allergies

- No known allergy **S**

## Objective

BP 130/80 mmHg; pulse 80 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 95% on room air; weight 76.6 kg; BMI 24.2 kg/m². All vital signs are synthetic.

Hemoglobin: 14.9 g/dL; White cell count: 8.1 10*3/uL; Absolute neutrophil count: 5.2 10*3/uL; Platelets: 258 10*3/uL; Creatinine: 1 mg/dL; eGFR (CKD-EPI 2021): 84 mL/min/1.73 m²; Glucose: 97 mg/dL; ALT: 23 U/L; AST: 22 U/L; Total bilirubin: 0.6 mg/dL; TSH: 1.9 mIU/L; Free T4: 1.2 ng/dL; Morning cortisol: 13.8 ug/dL; FEV1: 2.71 L; FEV1 percent predicted: 86%; FEV1/FVC: 0.73; DLCO: 23.6 mL/min/mm[Hg]; PHQ-9: 6; GAD-7: 7. All results are synthetic.

## Change since baseline

- Hemoglobin: 15.1 g/dL at baseline, 14.9 g/dL at this visit **S**
- White cell count: 8.4 10*3/uL at baseline, 8.1 10*3/uL at this visit **S**
- Platelets: 262 10*3/uL at baseline, 258 10*3/uL at this visit **S**
- Creatinine: 1 mg/dL at baseline, 1 mg/dL at this visit **S**
- eGFR (CKD-EPI 2021): 84 mL/min/1.73 m² at baseline, 84 mL/min/1.73 m² at this visit **S**
- Glucose: 94 mg/dL at baseline, 97 mg/dL at this visit **S**
- ALT: 22 U/L at baseline, 23 U/L at this visit **S**
- AST: 21 U/L at baseline, 22 U/L at this visit **S**
- Total bilirubin: 0.6 mg/dL at baseline, 0.6 mg/dL at this visit **S**

## Immunizations given today

- Pneumococcal conjugate vaccine PCV20, before chemoimmunotherapy **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well and upright; weight 76.6 kg; blood pressure 130/80, pulse 80; oxygen saturation 95 percent |
| Lymph nodes | No supraclavicular or cervical nodes |
| Respiratory | Breath sounds equal; scattered early-morning rhonchi that clear with a cough; no wheeze |
| Cardiovascular | Regular rhythm; no murmur; no edema |
| Extremities | No clubbing |
| Psychiatric | Attentive, asks direct questions and writes the answers down |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Adenocarcinoma of the left upper lobe, cT1c N1 M0, stage IIB** (C34.12). Non-small cell lung cancer found by his first screening CT while it can still be cured. Systematic EBUS staging shows hilar (N1) but not mediastinal spread, and PET-CT and brain MRI show no metastases. Because there is no EGFR or ALK alteration, nivolumab with platinum chemotherapy before surgery is an option that improves event-free survival and the chance of a complete pathologic response over surgery first, and the tumor board and Dr. Halvorsen-Pierce recommend it. His lung function allows a lobectomy (predicted postoperative FEV1 and DLCO both 63 percent). The KRAS G12C result does not change treatment now, but is kept for any recurrence. **S**
   - Cycle 1 of nivolumab, carboplatin and pemetrexed in eight days, on his chosen quit date.
   - Hepatitis B, hepatitis C and HIV tests drawn today.
   - Folic acid from today and vitamin B12 injection today; dexamethasone around each cycle.
   - Baseline thyroid, cortisol, liver and kidney tests today.
   - Restaging CT after cycle 3; thoracic surgery review before then.
   - PCV20 given today, before treatment.
2. **Nicotine dependence, cigarettes** (F17.210). Ready to quit now. Stopping smoking after a lung cancer diagnosis lowers surgical complications and improves survival, so it is part of his cancer treatment. Varenicline is the most effective single medicine; no history of seizures or mood disorder, and his kidney function is normal. **S**
   - Varenicline 0.5 mg daily for three days, then twice daily, then 1 mg twice daily from day 8.
   - Quit date on day 1 of cycle 1.
   - Quitline enrollment today; counseling at every visit.
3. **Lung-RADS 4X nodule** (R91.1). Explained by the diagnosis made today; superseded. **S**
   - Problem resolved.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Tissue diagnosis, PD-L1 and comprehensive biomarker testing | At diagnosis, before any systemic therapy; EGFR and ALK must be negative before chemoimmunotherapy | Up to date | Adenocarcinoma (TTF-1 positive); PD-L1 40 percent; KRAS G12C; EGFR, ALK, ROS1, BRAF, MET exon 14, RET, NTRK and HER2 negative on tissue and plasma |
| Imaging | Staging FDG PET-CT and brain MRI | At diagnosis for stage II or higher | Up to date | No mediastinal or distant disease on PET-CT; brain MRI clear |
| Examination | Invasive mediastinal staging | Before treatment when a central tumor or a positive hilar node is present (ACCP) | Up to date | EBUS: 11L positive; 4R, 4L, 7 and 10L negative |
| Referral | Thoracic multidisciplinary tumor board and thoracic surgery | Before treatment of every potentially resectable cancer | Up to date | Tumor board five days ago; thoracic surgery review booked after cycle 2 |
| Imaging | Pulmonary function: spirometry and DLCO with predicted postoperative values | Before lung resection | Completed today | FEV1 2.71 L (86 percent), FEV1/FVC 0.73, DLCO 23.6 (86 percent); predicted postoperative FEV1 and DLCO 63 percent: low risk, no exercise test needed |
| Laboratory | Immune-related adverse event laboratory panel: TSH, free T4, liver tests, creatinine and glucose | Baseline, then before each immunotherapy infusion | Completed today | TSH 1.9, free T4 1.2; ALT 23, AST 22, bilirubin 0.6; creatinine 1.0, eGFR 84; glucose 97 |
| Laboratory | Morning cortisol | Baseline and before each immunotherapy infusion (CMID); for symptoms | Completed today | 13.8 mcg/dL at 8 a.m. |
| Laboratory | Blood count with neutrophils and platelets | Baseline, then before each chemotherapy cycle | Completed today | Hemoglobin 14.9, white cells 8.1, neutrophils 5.2, platelets 258 |
| Laboratory | Hepatitis B, hepatitis C and HIV screening | Before systemic cancer therapy | Completed today | Drawn today; results to the oncology team before cycle 1 |
| Self-management | Tobacco use and cessation treatment | Every visit | Completed today | Still smoking a pack a day; ready to quit; varenicline started with a quit date of day 1 of cycle 1; quitline enrolled |
| Survey | Distress and depression screening | Every visit; PHQ-9 and GAD-7 at diagnosis and at treatment transitions | Completed today | PHQ-9 6 (item 9 scored 0), GAD-7 7; worried, supported at home |
| Examination | Dyspnea and cough assessment | Every visit | Completed today | Usual morning cough; no breathlessness |
| Self-management | Pulmonary rehabilitation (prehabilitation) | Before and after lung resection | Referred | Twice-weekly program from next week, alongside chemotherapy |
| Referral | Specialist palliative care | Early, for advanced or high-symptom-burden cancer | Not indicated | Resectable cancer treated with curative intent and no symptom burden; symptoms and distress are screened at each visit and referral will follow if needs arise |
| Imaging | Surveillance CT; routine brain MRI; PET-CT and ctDNA for surveillance | After curative treatment | Not indicated | Not yet applicable; PET-CT and circulating markers are not used for surveillance |
| Self-management | Equity: navigation and time to treatment | Each step of the pathway | Completed today | Diagnosis and plan 15 days after the screening CT; treatment starts in eight days; nurse navigator and transport help in place |

## Goal progress

- PET-CT, brain MRI, EBUS staging, tissue diagnosis, PD-L1 and comprehensive biomarker results and a tumor board plan within three weeks of the screening CT. Outcome by 2026-05-26: PET-CT in three days, brain MRI in four, EBUS in eight, tumor board in ten; PD-L1 and tissue sequencing back by the consultation, 15 days after the scan. **S**
- Stop smoking completely before treatment starts and stay stopped. In progress; target 2026-09-30. **S**
- Three cycles of chemoimmunotherapy before surgery without a delay of more than one week and without an immune-related adverse event of grade 2 or higher. In progress; target 2026-08-05. **S**
- Complete resection (R0) with systematic lymph node dissection within six weeks of the last cycle. In progress; target 2026-09-30. **S**
- Back to walking 3 km most mornings by three months after surgery. In progress; target 2026-09-30. **S**

## Medication changes

- Started: Varenicline 0.5 mg oral tablet: one tablet daily for three days, then one tablet twice daily for four days (starting week), with a quit date on day 8 **S**
- Started: Folic acid 1 mg oral tablet, one tablet daily from one week before the first pemetrexed dose until three weeks after the last **S**
- Started: Cyanocobalamin (vitamin B12) 1000 mcg intramuscular injection, one dose a week before the first pemetrexed dose (repeat every nine weeks while on pemetrexed) **S**

## Guideline basis

- CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026), Aether Forge
- NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026), National Comprehensive Cancer Network
- Silvestri GA, et al. Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: ACCP evidence-based clinical practice guidelines. Chest 2013;143(5 Suppl):e211S-e250S (PMID 23649440) (2013), American College of Chest Physicians
- Brunelli A, et al. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: ACCP evidence-based clinical practice guidelines. Chest 2013;143(5 Suppl):e166S-e190S (PMID 23649437) (2013), American College of Chest Physicians
- Forde PM, et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer (CheckMate 816). N Engl J Med 2022;386(21):1973-1985 (PMID 35403841) (2022), New England Journal of Medicine
- Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126 (PMID 34724392) (2021), American Society of Clinical Oncology
- Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions (2021), U.S. Preventive Services Task Force

## Follow-up

- Cycle 1 in eight days, on his quit date. Visit at cycle 2. Call the 24-hour oncology line for fever, breathlessness, a new cough, diarrhea, rash, yellow eyes or severe tiredness. **S**
- Next scheduled visit 2026-06-24: day 1 of cycle 2 of nivolumab with carboplatin and pemetrexed: toxicity, immune-related adverse event monitoring, smoking abstinence and prehabilitation. **S**
